Final CIFFREO Trial Results: No Benefit, Poor Safety for Fordadistrogene Movaparvovec in DMD Final results from the phase 3 CIFFREO trial of fordadistrogene movaparvovec demonstrated no improvement in ambulatory boys with DMD.

According to final findings from the phase 3 #CIFFREO trial, a single intravenous dose of fordadistrogene movaparvovec does not improve functional outcomes in ambulatory boys with Duchenne muscular dystrophy (#DMD). Reported in @thelancetneuro.bsky.social

Read more: https://bit.ly/4rE4GfL